Hunan Nucien Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Hunan Nucien Pharmaceutical has a total shareholder equity of CN¥1.3B and total debt of CN¥285.2M, which brings its debt-to-equity ratio to 22%. Its total assets and total liabilities are CN¥1.7B and CN¥396.3M respectively. Hunan Nucien Pharmaceutical's EBIT is CN¥388.1K making its interest coverage ratio 7.6. It has cash and short-term investments of CN¥644.6M.
Key information
22.0%
Debt to equity ratio
CN¥285.16m
Debt
| Interest coverage ratio | 7.6x |
| Cash | CN¥644.60m |
| Equity | CN¥1.30b |
| Total liabilities | CN¥396.29m |
| Total assets | CN¥1.70b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 688189's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥390.7M).
Long Term Liabilities: 688189's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥5.6M).
Debt to Equity History and Analysis
Debt Level: 688189 has more cash than its total debt.
Reducing Debt: 688189's debt to equity ratio has reduced from 108.4% to 22% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 688189 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 688189 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 22.9% per year.